U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Omalizumab (Xolair): Treatment of Adults and Adolescents (12 Years of Age and above) with Chronic Idiopathic Urticaria [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.

Cover of Omalizumab (Xolair)

Omalizumab (Xolair): Treatment of Adults and Adolescents (12 Years of Age and above) with Chronic Idiopathic Urticaria [Internet].

Show details

6ISSUES FOR CONSIDERATION

  • There is no evidence to inform the optimal interval between courses of treatment or to compare the efficacy (and thus the cost-effectiveness) of a dose titration from 150 mg to 300 mg.
  • Many of the CDR participating drug plans do not reimburse standard doses of several H1 antihistamines. Although the overall costs associated with H1 antihistamines are minimal and thus have little impact on the ICUR, they are typically an out-of-pocket expense for patients.
  • Costs of omalizumab (sourced from the Ontario Drug Benefit by the manufacturer) may be different if there are alternate pricing arrangements in place between the manufacturer and public drug plans. The price of omalizumab on the Alberta Drug Benefit formulary ($600 for 150 mg dose) is lower than on the Ontario Drug Benefit formulary.
  • In the manufacturer’s analysis, the costs associated with the administration of omalizumab (e.g., injection, nurse time, and physician time) are ▬▬▬▬. It should be noted that ▬▬▬▬.

6.1. Patient Input

Input was received from one patient group, the Canadian Skin Patient Alliance. In this input, patients reported that the occurrence of itchy hives cause a significant amount of anxiety, affect sleep, impact the foods they can consume, and influence the jobs they can obtain. The majority of patients also reported a decrease in self-confidence. Patients reported currently using over-the-counter antihistamines (doxepin, hydroxychloroquine, and prednisone) and that concerns with current treatment include treatment effectiveness and intolerable side effects. Patients expressed that omalizumab managed their symptoms better than previous treatments, effectively treating the skin eruptions and swelling. They also noted that the side effects with omalizumab were minimal.

Copyright © CADTH 2015.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK362678
Contents

Views

  • PubReader
  • Print View
  • Cite this Page

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...